Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.39 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 1/20 | 0.37 |
| ▸ | RORC | P51449 | 4/20 | 0.37 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.36 |
| ▸ | METAP2 | P50579 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | NSD2 | O96028 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.33 |
| ▸ | LOX | P28300 | 1/20 | 0.33 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.33 |
| ▸ | PDCD1LG2 | Q9BQ51 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2011220 | 0.84 | GPBAR1 (0.41) | GPBAR1FFAR4CETPMETAP2SCN9A | |
| SCHEMBL27780155 | 0.82 | GPBAR1 (0.41) | GPBAR1FFAR4CETPRORCMETAP2 | |
| SCHEMBL2003336 | 0.79 | RIPK1 (0.39) | GPBAR1FFAR4RORCSCN9ASCN5A | |
| SCHEMBL2004015 | 0.73 | NR3C1 (0.44) | GPBAR1CETPSCN9A | |
| SCHEMBL2011222 | 0.72 | GPBAR1 (0.40) | GPBAR1FFAR4SCN9ASCN5APDCD1LG2 | |
| SCHEMBL4550847 | 0.71 | ATM (0.51) | — | |
| Hydrochloric Acid SCHEMBL2713358 | 0.70 | ATM (0.50) | CSNK2A1 | |
| SCHEMBL30176060 | 0.69 | CSNK2A1 (0.47) | KCNN4CSNK2A1 | |
| SCHEMBL4374816 | 0.69 | CSNK2A1 (0.47) | KCNN4CSNK2A1 | |
| SCHEMBL2009916 | 0.68 | NAMPT (0.43) | FFAR4SCN9ASCN5APDCD1LG2CD274 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960365-B2 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2011-06-14 | — | — | US | disclosed |
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | N.V. ORGANON (NL) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149577-A1 | Compounds with medicinal effects due to interaction with the glucocorticoid receptor | NR3C1, NR3C2, MC2R | GPBAR1 65/4885FFAR4 84/4885CETP 3998/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.